RAS/MEK/ERK信号通路激活驱动原发性肝癌向胆管分化
研究利用肝特异性敲除Rb和p53并激活致癌Kras的基因工程小鼠模型,探究肝内胆管癌的起源细胞及RAS依赖性信号通路的作用。结果显示Kras突变肝内胆管癌主要起源于肝细胞,并激活PI3K/AKT和MEK/ERK信号;抑制MEK/ERK可诱导肿瘤向肝细胞样表型分化并伴随WNT/β-catenin激活。
要点
- Kras突变肝内胆管癌在小鼠中主要起源于肝细胞。
- KRAS下游PI3K/AKT和MEK/ERK信号均被激活。
- 抑制MEK/ERK诱导肿瘤向肝细胞样表型分化并激活WNT/β-catenin。
核心结论
- RAS依赖性通路调控肝癌分化,可解释人胆管癌中RAS突变频率高于肝细胞癌的现象。
研究设计与样本
- 采用肝特异性敲除Rb和p53并激活致癌Kras的基因工程小鼠模型。
主要发现
- 小鼠Kras突变肝内胆管癌主要起源于肝细胞,并激活KRAS下游PI3K/AKT和MEK/ERK信号。
- 靶向遗传失活PI3K/AKT或MEK/ERK通路均导致肿瘤生长延迟和分化显著改变。
- 降低PI3K/AKT信号促进更高分化的肿瘤,而失活MEK/ERK信号诱导向肝细胞样表型分化转换。
- 该分化转换伴随WNT/β-catenin信号激活,此通路在人肝细胞癌中常被激活。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: RAS mutations are frequently observed in human cholangiocarcinoma (CCA), while they are relatively rare in hepatocellular carcinoma (HCC). The role of RAS-dependent signalling pathways in CCA development is currently not well understood. OBJECTIVE: The objective of this study was to investigate RAS-dependent signalling pathways in CCA and their role in tumour development and differentiation. DESIGN: We used genetically engineered mouse models with liver-specific deletion of tumour suppressors Rb and p53 together with activation of oncogenic Kras to investigate the cell of origin in intrahepatic CCA and to elucidate the role of RAS-dependent signalling pathways in CCA development. RESULTS: In mice, Kras-mutant intrahepatic CCA develops primarily from hepatocytes and shows activation of PI3K/AKT and MEK/ERK signalling downstream of KRAS. Targeted genetic inactivation of each of these pathways leads to delayed tumour growth and profound alterations in tumour differentiation. Specifically, reduced PI3K/AKT signalling promotes more well-differentiated tumours, whereas the inactivation of MEK/ERK signalling induces a differentiation switch towards a more hepatocyte-like phenotype. This switch is accompanied by activation of WNT/β-catenin signalling, a pathway commonly activated in human HCC. CONCLUSIONS: These findings provide insights into the role of RAS-dependent pathways in liver cancer differentiation and offer a compelling explanation for the high prevalence of RAS mutations in human CCA compared with HCC.
引用
- Rösner T, Rupp C, Lechler C, et al. Activation of RAS/MEK/ERK signalling drives biliary differentiation in primary liver cancer. Gut. 2025. PMID: 40355258. doi:10.1136/gutjnl-2024-333238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。